Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $196,399,021 | $209,693,890 | $187,254,303 | $185,620,085 |
| - Cash | $11,459,000 | $13,393,000 | $7,517,000 | $12,407,000 |
| + Debt | $31,258,000 | $26,348,000 | $27,909,000 | $31,025,000 |
| Enterprise Value | $216,198,021 | $222,648,890 | $207,646,303 | $204,238,085 |
| Revenue | $51,722,000 | $46,660,000 | $43,461,000 | $43,974,000 |
| % Growth | 10.8% | 7.4% | -1.2% | – |
| Gross Profit | $38,895,000 | $34,188,000 | $31,879,000 | $32,239,000 |
| % Margin | 75.2% | 73.3% | 73.4% | 73.3% |
| EBITDA | $20,715,000 | $18,255,000 | $14,682,000 | $30,914,000 |
| % Margin | 40.1% | 39.1% | 33.8% | 70.3% |
| Net Income | $11,941,000 | $14,850,000 | $6,955,000 | $24,021,000 |
| % Margin | 23.1% | 31.8% | 16% | 54.6% |
| EPS Diluted | 5.87 | 7.1 | 3.17 | 10.63 |
| % Growth | -17.3% | 124% | -70.2% | – |
| Operating Cash Flow | $17,619,000 | $14,458,000 | $14,236,000 | $15,071,000 |
| Capital Expenditures | -$3,814,000 | -$2,753,000 | -$2,239,000 | -$2,556,000 |
| Free Cash Flow | $13,805,000 | $11,705,000 | $11,997,000 | $12,515,000 |